[Preliminary study of the use of low-molecular weight heparin to prevent XXXX risk].

@entity1 @entity28052 @entity548 @entity11270 @entity8258 @entity715 @entity2120
This study involved two stages: In vitro study. Three LMWHs, @entity11270 - @entity28052 (Choay) and @entity2120 (Pharmuka), were compared to standard heparin, SH (Choay), and to a high-molecular-weight heparin, @entity8258 (Choay), which particularly revealed a dissociation of anti-Xa (++) and anti-IIa (+) activities for the LMWHs: (table: see text) In vivo study. Healthy volunteers. Subcutaneously injections of @entity2120 or @entity28052 according to various protocols (rythm of injections, dosage). For both LMWHs, the dissociation of anti-Xa and anti-IIa activities reoccurs in vivo. A peak of anti-Xa effect was observed 3 to 4 hours after the injections. The duration period of this activity is about 12 hours. The importance of the global platelet tests HT and TEG (modified for the highest doses) should be noted. Study of @entity548 tendencies in @entity1 with slight @entity715 risk. From this preliminary study, protocols with @entity11270 , @entity28052 and @entity2120 are proposed for the prevention of @entity715 risk in orthopaedic surgery (injections at 12-hour intervals).
